Adenosine Deaminase - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Adenosine Deaminase

The Experts below are selected from a list of 31344 Experts worldwide ranked by ideXlab platform

Adenosine Deaminase – Free Register to Access Experts & Abstracts

Catherine Fenselau – One of the best experts on this subject based on the ideXlab platform.

  • Primary structure of bovine Adenosine Deaminase
    Journal of pharmaceutical and biomedical analysis, 1996
    Co-Authors: Michele Kelly, Martha M. Vestling, Constance M. Murphy, S. Hua, T. Sumpter, Catherine Fenselau

    Abstract:

    Derivatized bovine Adenosine Deaminase is used in enzyme replacement therapy and as an adjunct to gene therapy against severe combined immunodeficiency syndrome. Although a gene sequence is known for human Adenosine Deaminase, the structure of the bovine enzyme has not been characterized. Structure studies using mass spectrometry are reported here that evaluate sequence, processing, post-translational modifications and the extent of homology between the human protein and its therapeutic surrogate.

Maria Grazia Roncarolo – One of the best experts on this subject based on the ideXlab platform.

  • Gene therapy for Adenosine Deaminase deficiency.
    Current opinion in allergy and clinical immunology, 2003
    Co-Authors: Alessandro Aiuti, Francesca Ficara, Federica Cattaneo, Claudio Bordignon, Maria Grazia Roncarolo

    Abstract:

    Purpose of review Gene therapy for severe combined immunodeficiency due to Adenosine Deaminase deficiency has moved from the early trials of safety and feasibility to recent studies demonstrating efficacy and clinical benefit. This review describes the latest advances in gene therapy trials for this condition using peripheral blood lymphocytes or hematopoietic progenitors. Recent findings In the first patients with severe combined immunodeficiency due to Adenosine Deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic Adenosine Deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine Adenosine Deaminase conjugated to polyethylene-glycol (PEG-ADA). A recent report showed that discontinuation of PEG-ADA resulted in a strong selective advantage of gene corrected T cells associated with restoration of T cell functions and antibody responses to neoantigen, but incomplete correction of the metabolic defect. Follow-up studies in patients treated with engineered hematopoietic progenitors in the early trials revealed low marking levels of long-term living progenitors and limited clinical effect. Recently, an improved gene transfer protocol in bone marrow CD34+ cells combined with low-dose busulfan resulted in multilineage, stable engraftment of transduced progenitors at substantial levels, restoration of immune functions, correction of the Adenosine Deaminase metabolic defect, and proven clinical benefit, in the absence of PEG-ADA. Overall, no adverse effect or toxicity has been observed in patients treated with Adenosine Deaminase gene transfer in mature lymphocytes or hematopoietic progenitors. Summary Gene transfer in hematopoietic stem cells combined with nonmyeloablative conditioning is efficacious and might be extended to the treatment of other inherited and acquired disorders of the hematopoietic system.

Michele Kelly – One of the best experts on this subject based on the ideXlab platform.

  • Primary structure of bovine Adenosine Deaminase
    Journal of pharmaceutical and biomedical analysis, 1996
    Co-Authors: Michele Kelly, Martha M. Vestling, Constance M. Murphy, S. Hua, T. Sumpter, Catherine Fenselau

    Abstract:

    Derivatized bovine Adenosine Deaminase is used in enzyme replacement therapy and as an adjunct to gene therapy against severe combined immunodeficiency syndrome. Although a gene sequence is known for human Adenosine Deaminase, the structure of the bovine enzyme has not been characterized. Structure studies using mass spectrometry are reported here that evaluate sequence, processing, post-translational modifications and the extent of homology between the human protein and its therapeutic surrogate.